Searching across hundreds of databases
Current genome-editing systems generally rely on inducing DNA double-strand breaks (DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by DSBs can have deleterious effects. CRISPR/Cas9 system has recently been repurposed to enable target gene activation, allowing regulation of endogenous gene expression without creating DSBs. However, in vivo implementation of this gain-of-function system has proven difficult. Here, we report a robust system for in vivo activation of endogenous target genes through trans-epigenetic remodeling. The system relies on recruitment of Cas9 and transcriptional activation complexes to target loci by modified single guide RNAs. As proof-of-concept, we used this technology to treat mouse models of diabetes, muscular dystrophy, and acute kidney disease. Results demonstrate that CRISPR/Cas9-mediated target gene activation can be achieved in vivo, leading to measurable phenotypes and amelioration of disease symptoms. This establishes new avenues for developing targeted epigenetic therapies against human diseases. VIDEO ABSTRACT.
Pubmed ID: 29224783 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A commercial graphing software company that offers scientific software for statistical analyses, curve fitting and data analysis. It offers four programs: Prism, InStat, StatMate and QuickCalcs.
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets Histone H3 (tri methyl K4)
View all literature mentionsThis unknown targets Recombinant fusion protein containing N-terminal region of mouse PDX-1
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets UTRN
View all literature mentionsThis monoclonal targets Human FOXA2
View all literature mentionsThis polyclonal targets Insulin
View all literature mentionsThis polyclonal targets Laminin antibody produced in rabbit
View all literature mentionsMus musculus with name C57BL/10ScSn-Dmdmdx/J from IMSR.
View all literature mentionsMus musculus with name C57BL/6J from IMSR.
View all literature mentionsMus musculus with name STOCK Gt(ROSA)26Sortm1.1(CAG-cas9*.-EGFP)Fezh/J from IMSR.
View all literature mentionsMus musculus with name ICR/HaJ from IMSR.
View all literature mentionsMus musculus with name STOCK Gt(ROSA)26Sortm1.1(CAG-cas9*.-EGFP)Fezh/J from IMSR.
View all literature mentionsMus musculus with name ICR/HaJ from IMSR.
View all literature mentionsThis polyclonal targets Histone H3 (tri methyl K4)
View all literature mentionsThis unknown targets Recombinant fusion protein containing N-terminal region of mouse PDX-1
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets UTRN
View all literature mentionsThis monoclonal targets Human FOXA2
View all literature mentionsThis polyclonal targets Insulin
View all literature mentionsThis polyclonal targets Laminin antibody produced in rabbit
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
